Investor Brand Network (“IBN”) recently announced the release of its latest episode of The Bell2Bell Podcast, featuring Amir Reichman, CEO of BiondVax Pharmaceuticals (NASDAQ: BVXV). The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries – like BiondVax’s innovative platform technology using alpaca-derived nanosized antibodies, known as Nanobodies (NanoAbs) (https://ibn.fm/6TsnQ). These NanoAbs address infectious and autoimmune diseases with large unmet medical needs, such as COVID-19, psoriasis, psoriatic arthritis, asthma, and macular degeneration.
BiondVax, in collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany, is developing a pipeline of innovative NanoAbs that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.
This recent interview between podcast host Stuart Smith and Reichman is a follow-up from December 2022 – beginning with BiondVax’s recent achievements, as detailed in a letter to shareholders issued late last year. Reichman told Smith that the company successfully executed a round of financing at the end of 2022, raising about $8 million. BiondVax also in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (IL-17) for the treatment of psoriasis, HS, and other important indications. BiondVax is now fast on the trail of developing what could be a very promising drug.
Autoimmune diseases are often chronic and require patients to take drugs for life, with annual sales for current anti-interleukin-17 monoclonal antibodies totaling about $7.5 billion. With their NanoAbs, BiondVax aims to generate a highly potent, highly specific drug that is safe to use for the large and underserved population of mild-to-moderate psoriasis patients. BiondVax expects to complete a proof-of-concept trial later this year, followed by human clinical trials.
Reichman explained that there are currently several treatment options on the market for psoriasis patients, such as, for example, creams and other topical drugs, biologics, and oral drugs for plaque psoriasis patients. However, the topicals are not highly sophisticated drugs, and they come with considerable side effects. “When a person needs to take steroids once in a while for an infection, they can tolerate it, but when you need to take steroids for an autoimmune disease with chronic inflammation, you create tolerance and deal with potential side effects,” the BiondVax CEO explained.
As for biologics, they are highly potent, but they are restricted to moderate and severe cases of psoriasis, which accounts for only 15% of patients with psoriasis. “The 85% that are left have to choose between drugs based on 1960s and 1970s technology. There hasn’t been much breakthrough in recent years to serve these patients,” Reichman added.
Additionally, BiondVax has also begun to offer contract development and manufacturing organization (“CDMO”) services. The CDMO services were designed to keep the BiondVax team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s primary focus – its potentially blockbuster NanoAb pipeline.
For more information, visit the company’s website at www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the…
The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”) Sapu-003…
Approximately 20% of people in the U.S. live in a rural area, and they face…
On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant…
Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer.…
Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been…